VBI Vaccines Profit Margin

The latest profit margin for VBIV is -881.79% as of March 2024. That compares with -8984.8% in the prior-year period — up 90.2% year over year. That is below the Healthcare sector average of 13.89%. Investors often review this figure alongside VBI Vaccines's historical trend and sector peers before judging valuation or financial health.

Over the past year, VBIV's profit margin moved from -8984.8% to -881.79% — a 90.2% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in VBI Vaccines's valuation or profitability profile.

Against Healthcare companies, VBIV currently prints -881.79% for profit margin, while the sector average sits near 13.89%. That is roughly 6447.0% below the sector mean. Large gaps often invite a closer look at VBI Vaccines's growth, margins, and balance sheet.

Profit Margin shows how effectively VBI Vaccines converts resources into returns. At -881.79%, VBIV may look efficient or underperforming depending on peer benchmarks and trend direction. That compares with -8984.8% in the prior-year period — up 90.2% year over year. Pair the percentage with revenue growth and leverage for a fuller health check.

After noting VBIV's profit margin (-881.79%), review year-over-year change from -8984.8%, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.